Science Explorer Back to mapMap
Discussion
Topic · Dermatology

Cutaneous lymphoproliferative disorders research

Cutaneous lymphoproliferative disorders research is a research topic within Dermatology. Science Explorer counts 20k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the classification, staging, treatment, and prognosis of cutaneous lymphomas, with a specific emphasis on mycosis fungoides and Sézary syndrome. It includes discussions on the WHO-EORTC classification, survival outcomes, prognostic factors, and various treatment options such as bexarotene and denileukin diftitox. The cluster also addresses the incidence patterns, genomic landscape, and molecular profiling of cutaneous T-cell lymphomas.

  • Cutaneous Lymphomas
  • Mycosis Fungoides
  • Sézary Syndrome
  • EORTC Classification
  • T-Cell Lymphoma
  • CD30+ Lymphoproliferative Disorders
  • Primary Cutaneous Lymphomas
  • Bexarotene Treatment
  • Prognostic Factors
  • Clinical End Points
Research works
20k
fractional, since 1950
In the world top 10%
2.1k
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+11%
the tick is no change
Largest producer
United States
40% of the 10 largest, 2022-now
Cutaneous lymphoproliferative disorders research

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Cutaneous lymphoproliferative disorders research research?

By volume, the United States and China publish the most (1.3k and 482 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.3k works
  2. 2 China 482 works
  3. 3 India 262 works
  4. 4 Italy 205 works
  5. 5 Germany 205 works
  6. 6 France 197 works
  7. 7 Japan 186 works
  8. 8 Spain 166 works
  9. 9 Brazil 161 works
  10. 10 United Kingdom 132 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 39.7%China: 14.6%India: 7.9%Italy: 6.2%6 others listed: 31.6%40%largest
United States1,312 · 39.7%China482 · 14.6%India262 · 7.9%Italy205 · 6.2%6 others listed1,046 · 31.6%

Shares of the rows listed above, not of the whole node.

Which institutions lead Cutaneous lymphoproliferative disorders research research?

By volume in 2022-now, Harvard University publishes the most Cutaneous lymphoproliferative disorders research research, followed by The University of Texas MD Anderson Cancer Center and Mayo Clinic.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 53 works
  2. 2 The University of Texas MD Anderson Cancer CenterUnited States 50 works
  3. 3 Mayo ClinicUnited States 42 works
  4. 4 All India Institute of Medical SciencesIndia 32 works
  5. 5 University of PennsylvaniaUnited States 29 works
  6. 6 Peking UniversityChina 28 works
  7. 7 Memorial Sloan Kettering Cancer CenterUnited States 27 works
  8. 8 InsermFrance 26 works
  9. 9 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 26 works
  10. 10 Cornell UniversityUnited States 26 works

Who are the leading researchers in Cutaneous lymphoproliferative disorders research?

The most-cited researchers publishing on Cutaneous lymphoproliferative disorders research include Gad A. Getz, Matthew M. Meyerson and Hagop M. Kantarjian.

  1. 1 Gad A. Getz United States 364k citations
  2. 2 Matthew M. Meyerson United States 280k citations
  3. 3 Hagop M. Kantarjian United States 273k citations
  4. 4 Jean‐Louis Vincent Belgium 262k citations
  5. 5 Carlo La Vecchia Italy 258k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Cutaneous lymphoproliferative disorders research?

The most cited paper in Cutaneous lymphoproliferative disorders research is "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" (Steven H. Swerdlow, Elı́as Campo, Stefano Aldo Pileri et al., 2016), with 7,935 citations. Next come "Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma" (6,098) and "Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma" (5,108).

Most cited papers
#PaperReleasedCitations
1 The 2016 revision of the World Health Organization classification of lymphoid neoplasms Steven H. Swerdlow, Elı́as Campo, Stefano Aldo Pileri et al. · Blood Open access 15 Mar 2016 7,935
2 Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Sattva Swarup Neelapu et al. · New England Journal of Medicine Open access 10 Dec 2017 6,098
3 Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma Bernard J. Poiesz, Francis W. Ruscetti, Adi F. Gazdar et al. · Proceedings of the National Academy of Sciences Open access Dec 1980 5,108
4 WHO-EORTC classification for cutaneous lymphomas Rein Willemze · Blood Open access 3 Feb 2005 3,826
5 T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson et al. · The Lancet Open access 13 Oct 2014 2,968
All 100 most cited papers, with filters and sorting

Where is Cutaneous lymphoproliferative disorders research research done?

The largest centres of Cutaneous lymphoproliferative disorders research research in 2022-now are New York (United States), Beijing (China), Houston (United States) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Houston.

Largest cities, 2022-now

  1. 1 New YorkUnited States 98 works
  2. 2 BeijingChina 96 works
  3. 3 HoustonUnited States 69 works
  4. 4 ParisFrance 69 works
  5. 5 PhiladelphiaUnited States 60 works
  6. 6 BostonUnited States 49 works
  7. 7 ShanghaiChina 45 works
  8. 8 LondonUnited Kingdom 44 works
  9. 9 TokyoJapan 41 works
  10. 10 São PauloBrazil 41 works

Where it is the local speciality

  1. HoustonUS · 69.4 works6.5×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Cutaneous lymphoproliferative disorders research than the world average.

See Cutaneous lymphoproliferative disorders research on the map

Where is the best place to study Cutaneous lymphoproliferative disorders research?

Among universities, judged by research, Harvard University, Leiden University and Stanford University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 16.22%fractional works in this field (log) →share of work in the world top 10% →Harvard UniversityLeiden UniversityPeking UniversityStanford University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 81.919.1%4.3×54 +0.5%
2Leiden UniversityNetherlands 74.217.8%6.2×13 +29.1%
3Stanford UniversityUnited States 69.215.8%3.8×22 +8.6%
4Peking UniversityChina 63.816.3%3.5×28 +43.3%
5University of PennsylvaniaUnited States 63.613.4%7.1×29 +8.0%
6Huazhong University of Science and TechnologyChina 62.724.3%2.1×15 +628.9%
7Cornell UniversityUnited States 62.614.1%5.0×26 +8.6%
8University of MichiganUnited States 57.018.8%2.4×14 +25.6%
9Columbia UniversityUnited States 55.09.7%4.8×20 +17.9%
10Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 54.412.9%6.3×26 +48.1%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Cutaneous lymphoproliferative disorders research, country by country

Is Cutaneous lymphoproliferative disorders research research growing?

Output in 2022-2025 was 11% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Cutaneous lymphoproliferative disorders research.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Cutaneous lymphoproliferative disorders research as a percentage of every work published that year, 0.016% in 2024.

still counting0.010%0.020%0.030%Cutaneous lymphoproliferative disorders research0.020% in 202519801990200020102020

Fractional works of Cutaneous lymphoproliferative disorders research over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Cutaneous lymphoproliferative disorders research11.0% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Cutaneous lymphoproliferative disorders research. Posts are plain text and can be reported.